Phase 1 trial in 35 previously vaccinated adults: live NDV-HXP-S COVID-19 vaccine given intranasally, intramuscularly or both v placebo had only grade 1-2 adverse events; exploratory immune responses were variable. Not powered for significance.
RCTn = 35
Liu et al. Phase 1 trial of intranasal NDV-HXP-S in previously vaccinated adults